Should Psychedelics Be Legal Medicine?
The FDA rejected MDMA therapy in 2024; Phase 2 PTSD trials showed 67% remission. Oregon is running licensed psilocybin clinics. Most promising psychiatric breakthrough in 50 years — or a hype cycle with a blinding problem? Two debaters, opposing sides — you score who makes the stronger case.
Friday, October 9, 2026 · 7:00 PM EDT
Scheduled date passed
What’s at stake
If the evidence holds, 50 years of Schedule I classification was a catastrophic error in medical history. If it doesn't replicate, enormous credibility has been misplaced.
The opposing positions
Resolved: Psilocybin, MDMA, and other psychedelics should be licensed as regulated prescription treatments
PRO: The evidence demands access
These compounds have the best treatment-resistant depression and PTSD data in a generation; scheduling them as Schedule I while fentanyl kills 100,000 Americans per year is a policy failure with a body count.
- Phase 2 MAPS trials showed 67% of MDMA-treated PTSD patients no longer met the diagnostic criteria at 12 months, a remission rate no existing treatment approaches, and psilocybin trials at Johns Hopkins and NYU show comparable results for treatment-resistant depression.
- Psilocybin mushrooms, peyote, and ayahuasca each have a documented history of safe ceremonial and therapeutic use spanning millennia; the unknown-risk framing applies to rapid pharmaceutical commercialization, not the substances themselves.
- The FDA's 2024 rejection was based on trial-design concerns, not evidence of harm; the solution is a clear licensing pathway with rigorous therapist certification requirements, not continued prohibition of the most promising psychiatric drug class in 50 years.
CON: The hype has outrun the science
The phase-3 trials failed; the blinding problem is structurally unsolvable; and commercializing powerful psychoactive drugs before we understand them is a mistake we will spend decades cleaning up.
- The most rigorous MDMA trial, which the FDA reviewed in 2024, showed the drug did not beat placebo in one of two phase-3 studies, with a blinding problem so severe that 'double-blind' is fiction; participants always know they took the drug, making expectancy effects inseparable from pharmacological effects.
- Psychedelics carry real risks: triggering latent psychosis, cardiac events with MDMA, and serious ethical violations in therapeutic contexts: three therapists in MAPS's own trials were found to have sexually abused patients during or after sessions.
- The set, setting, and therapeutic relationship appear to drive most of the effect; the commercialization model of brief pill plus minimal therapy strips out what works while profiting from the brand, at the expense of patient safety.
Contribute now
Add your perspective
Record a 60-second take or write an argument. Your contribution can stand on its own, and the discussion stays open.
Start here
Contribute now
A 60-second video or a written argument. You do not need an opponent to get started.
Share only material you have permission to make public.
Optional
Exchange responses
Choose whether to be paired. An exchange starts only after both people accept.
Pairing is not available on this page yet. You can still contribute or respond to a public take.
At a set time
Live attendance
Live attendance is separate from your contribution. Check the showcase details for any scheduled session.
Check showcase detailsPRO: The evidence demands access
CON: The hype has outrun the science
1 video“Phase 2 MAPS trials showed 67% of MDMA-treated PTSD patients no longer met the diagnostic criteria at 12 months — a remission rate no existing treatment approaches. Psilocybin trials at Johns Hopkins and NYU show comparable results for treatment-resistant depression. For conditions that have defeated every available treatment, the evidence base is remarkable.”
“Psilocybin mushrooms, peyote, and ayahuasca each have documented histories of safe ceremonial and therapeutic use spanning millennia. The unknown-risk framing applies to rapid pharmaceutical commercialization, not to the substances themselves. Safety profiles are better understood for these compounds than for many FDA-approved medications.”
“The most rigorous MDMA trial the FDA reviewed in 2024 failed to beat placebo in one of two Phase 3 studies. The blinding problem is severe: participants almost always know they took the drug, making expectancy effects inseparable from pharmacological ones. The effect size may be mostly placebo amplified by intense therapeutic context.”
“Psychedelics carry real risks: triggering latent psychosis, cardiac events with MDMA, and serious ethical violations in therapeutic contexts. Three therapists in MAPS's own trials were found to have sexually abused patients during or after sessions. The vulnerability of people in altered states creates abuse risks that are not hypothetical.”
The debate format
Follow each side’s case through questions, rebuttals and closing statements.
- 4 min
Opening Argument
PRO · opening case
PRO · opening case
- 4 min
Cross-Examination
CON questions PRO
CON questions PRO
- 4 min
Opening Argument
CON · opening case
CON · opening case
- 4 min
Cross-Examination
PRO questions CON
PRO questions CON
- 3 min
Rebuttal
PRO
PRO
- 3 min
Rebuttal
CON
CON
- 3 min
Closing Statement
PRO · final case
PRO · final case
- 3 min
Closing Statement
CON · final case
CON · final case
- —
Audience Vote
You pick the winner
You pick the winner
Get debate updates
Leave your email for announcements about this debate.
Debate schedule
Friday, October 9, 2026 · 7:00 PM EDT
Get Involved
Open debate runs on the people who show up. Tell us how you want to be part of it.
More Debates
Structured debates on the ideas that matter most. You score who makes the stronger case.
Should the Four-Day Work Week Become Standard?
Should Supreme Court Justices Have Term Limits?
Should Race-Conscious College Admissions Be Restored?
